8-K current report · filed Jul 23, 2026

West Pharmaceutical Services (WST) 8-K Current Report: July 23, 2026

Item EX-99.2Item EX-99.1Item 2.02Item 7.01WST overview

Short answer

West Pharmaceutical Services (WST) filed an 8-K current report with the SEC on July 23, 2026 reporting Item EX-99.2 (Exhibit EX-99.2), Item EX-99.1 (Exhibit EX-99.1), Item 2.02 (Results of Operations and Financial Condition), Item 7.01 (Regulation FD Disclosure). Second-quarter 2026 financial results announced on July 23, 2026.

West Pharmaceutical Services 8-K event analysis

AI summary of each reported item and its exhibits

Item 2.02 · Results of Operations and Financial Condition

  • Second-quarter 2026 financial results announced on July 23, 2026
  • Detailed results and management commentary provided in Exhibit 99.1, the accompanying earnings release

Item 7.01 · Regulation FD Disclosure

  • Investor presentation supporting the Item 2.02 earnings disclosure, available via West Pharmaceutical Services’ investor website and Exhibit 99.2
  • Presentation materials may provide additional context on operating results and management commentary beyond the earnings release

Item EX-99.1 · Exhibit EX-99.1

  • Q2 net sales $872.3M, up 13.8%, with organic growth of 12.7%, confirming strong demand momentum
  • Adjusted EPS $2.37, up 28.8%, while adjusted operating margin expanded to 22.6% from 20.3%
  • Biologics organic growth 29.2% and HVP Delivery Devices organic growth 29.2%, driving Proprietary Products performance
  • Full-year sales guidance raised to $3.345B-$3.380B and adjusted EPS to $8.85-$9.05
  • Share repurchases totaled $454.3M for 1.8M shares, while free cash flow reached $128.0M

Item EX-99.2 · Exhibit EX-99.2

  • Q2 net sales $872.3M, up 13.8% reported and 12.7% organically, led by biologics and high-value products
  • Adjusted EPS $2.37, up 28.8%, with adjusted operating margin expanding 230 basis points to 22.6%
  • Proprietary Products organic growth 15.5%, versus West Vantage organic growth 0.8% and margin decline to 8.6%
  • Biologics revenue $374.8M, up 29.2% organically, while GLP-1 represented 10% of total company revenue
  • 2026 guidance maintained: revenue $3.345B to $3.380B and adjusted EPS $8.85 to $9.05; H1 share repurchases totaled $454.3M

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other West Pharmaceutical Services 8-K filings

Get the next WST 8-K as it lands

Follow WST for push alerts, or ask the research agent what this filing means.